Skip to content
DataLookout
Menu

KANDELA-302NCT07492641

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 14 versions: 14 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 206 → 241 locations
  2. Minor Trial sites expanded: 189 → 206 locations
  3. Minor Trial sites expanded: 162 → 189 locations
  4. Notable Eligibility criteria expanded, about 7 words
    • Trial sites expanded: 108 → 162 locations
    • Secondary endpoints: details revised at 1 of 9 entries
  5. Minor Trial sites expanded: 90 → 108 locationsv10
  6. Minor Trial sites expanded: 74 → 90 locationsv9
  7. Minor Trial sites expanded: 62 → 74 locationsv8
  8. Minor Trial sites expanded: 30 → 62 locationsv7
  9. Minor Trial sites expanded: 13 → 30 locationsv6
  10. Minor Start date: May 20, 2026 to May 22, 2026v5
  11. Minor Trial sites expanded: 4 → 13 locationsv4
  12. Notable Recruitment opened
    • Trial sites expanded: 0 → 4 locations
    • Start date changed from estimate of May 11, 2026 to May 20, 2026
    v3
  13. Notable Eligibility criteria expanded, about 27 words
    • Secondary endpoints: 8 to 9
    v2
  14. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)
Timeframe: Up to approximately 4 years

Secondary (9)

Overall Survival (OS)
Overall Response Rate (ORR)
Duration of Response (DOR)
PFS Determined by Investigator
Clinical Benefit Rate (CBR)
Show 4 moreShow less
Time to Response (TTR)
Number of Participants with Adverse Events (AEs)
Change from Baseline in European Organisation for Research and Treatment of Cancer (EORTC)-Item Library (IL)454.
Progression-Free Survival 2 (PFS2)

Arms and interventions

Arm A: BGB-43395 + LetrozoleExperimental

Participants will receive BGB-43395 in combination with letrozole.

Arm B: Cyclin-Dependent Kinase 4/6 Inhibitor + LetrozoleActive comparator

Participants will receive either abemaciclib, palbociclib, or ribociclib based on the Investigator's choice in combination with letrozole.

Drugs: BGB-43395, Letrozole, Abemaciclib, Palbociclib, Ribociclib

Sites

241 sites in 16 countries

United States 84, China 33, South Korea 25, Japan 19, Brazil 13, Spain 12, Malaysia 9, Australia 8, Poland 8, Turkey (Türkiye) 8, France 7, Germany 4, Italy 4, Taiwan 4, United Kingdom 2, Puerto Rico 1